TKNO
NASDAQAlpha Teknova Inc.
News25/Ratings10
News · 26 weeks18-50%
2026-04-262026-10-18
Mix1090d
- Analyst3(30%)
- Other3(30%)
- Earnings2(20%)
- SEC Filings2(20%)
Latest news
25 items- PRTeknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation SystemHOLLISTER, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), and Pluristyx, Inc. ("Pluristyx"), today announced that Pluristyx is completing a Type II Drug Master File (DMF) for the PluriFreeze™ cryopreservation system for submission to the U.S. Food and Drug Administration (FDA). The DMF will support drug makers seeking to incorporate PluriFreeze into their clinical development and manufacturing programs. Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, and is the exclusive manufacturer and distributor of PluriFreeze in the United States a
- ANALYSTJefferies initiated coverage on Alpha Teknova with a new price targetJefferies initiated coverage of Alpha Teknova with a rating of Buy and set a new price target of $9.00
- PRTeknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag FillingHOLLISTER, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today introduced the Fill-Tek™ Dispensing System. Fill-Tek is a proprietary single-use bag dispensing capability that fills an entire custom reagent order across multiple bag sizes and quantities as a single lot. The Fill-Tek system removes the per-bag-size minimums that come with fixed manifold designs, so manufacturers can order the formats their process calls for rather than the formats the fill line requires. "Your process is one of a ki
- ANALYSTAlpha Teknova upgraded by BTIG Research with a new price targetBTIG Research upgraded Alpha Teknova from Neutral to Buy and set a new price target of $8.00
- SECSEC Form 10-Q filed by Alpha Teknova Inc.10-Q - Alpha Teknova, Inc. (0001850902) (Filer)
- SECAlpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Alpha Teknova, Inc. (0001850902) (Filer)
- PRTeknova Reports Second Quarter 2026 Financial ResultsSecond quarter 2026 total revenue was $12.2 million, up 18% over the same quarter prior yearCompany raises 2026 revenue guidance to $45-47 millionLaunched proprietary AI-powered Build-Tek™ custom order configurator, giving developers a faster path from preclinical to clinical manufacturing HOLLISTER, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2026. "We delivered more than $12 million in quarterly revenue fo
- PRTeknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in MinutesHOLLISTER, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today launched Build-Tek™, an AI-powered custom order configurator that enables developers of therapies and diagnostics to design complex custom products and submit a request for quote in minutes. Build-Tek expands on the original buffer configurator Teknova introduced in 2024, extending custom configuration functionality across the Company’s full range of products, container formats, and manufacturing grades through a highly interactive self-
- ANALYSTRoth Capital initiated coverage on Alpha Teknova with a new price targetRoth Capital initiated coverage of Alpha Teknova with a rating of Buy and set a new price target of $7.00
- PRTeknova to Report Second Quarter 2026 Financial Results on August 5, 2026HOLLISTER, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, following the close of market. Teknova will host a webcast and conference call on Wednesday, August 5, 2026, beginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like
- INSIDERDirector Demski Martha J disposed of 12,000 shares and acquired 12,000 shares, closing all direct ownership in the company (SEC Form 4)4 - Alpha Teknova, Inc. (0001850902) (Issuer)
- INSIDERSEC Form 4 filed by Director Vos Alexander4 - Alpha Teknova, Inc. (0001850902) (Issuer)
- INSIDERSEC Form 4 filed by Director Robertson Brett4 - Alpha Teknova, Inc. (0001850902) (Issuer)
- INSIDERSEC Form 4 filed by Director Demski Martha J4 - Alpha Teknova, Inc. (0001850902) (Issuer)
- SECAlpha Teknova Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Alpha Teknova, Inc. (0001850902) (Filer)
- SECSEC Form 10-Q filed by Alpha Teknova Inc.10-Q - Alpha Teknova, Inc. (0001850902) (Filer)
- SECAlpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics8-K - Alpha Teknova, Inc. (0001850902) (Filer)
- PRTeknova Reports First Quarter 2026 Financial ResultsFirst quarter 2026 total revenue was $11.1 million, up 13% over the same quarter prior yearCompany reaffirms 2026 revenue guidance of $42-44 million HOLLISTER, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2026. "We had a great start to 2026," said Stephen Gunstream, President and Chief Executive Officer at Teknova. "The substantial investments we've made since 2021, combined with an improved market backdrop, p
- PRTeknova to Report First Quarter 2026 Financial Results on May 6, 2026HOLLISTER, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2026, on Wednesday, May 6, 2026, following the close of market. Teknova will host a webcast and conference call on Wednesday, May 6, 2026, beginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to p
- SECSEC Form DEFA14A filed by Alpha Teknova Inc.DEFA14A - Alpha Teknova, Inc. (0001850902) (Filer)
- SECSEC Form DEF 14A filed by Alpha Teknova Inc.DEF 14A - Alpha Teknova, Inc. (0001850902) (Filer)
- INSIDERSEC Form 4 filed by General Counsel and CCO Terrill Damon4 - Alpha Teknova, Inc. (0001850902) (Issuer)
- INSIDERChief Financial Officer Lowell Matthew bought $87,616 worth of shares (40,000 units at $2.19), increasing direct ownership by 31% to 168,376 units (SEC Form 4)4 - Alpha Teknova, Inc. (0001850902) (Issuer)
- INSIDERPresident and CEO Gunstream Stephen bought $55,801 worth of shares (26,000 units at $2.15), increasing direct ownership by 11% to 269,497 units (SEC Form 4)4 - Alpha Teknova, Inc. (0001850902) (Issuer)
- SECSEC Form 10-K filed by Alpha Teknova Inc.10-K - Alpha Teknova, Inc. (0001850902) (Filer)
TKNO FAQ
6 questionsWhere does TKNO stock trade?
Alpha Teknova Inc. (TKNO) is listed on NASDAQ.What sector and industry is TKNO in?
Alpha Teknova Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did Alpha Teknova Inc. go public?
Alpha Teknova Inc. (TKNO) completed its IPO in 2021.What are analysts saying about TKNO?
Alpha Teknova Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy with a $900.00 price target on 2026-09-17. Recent price targets range from $700.00 to $2700.00.What companies are similar to TKNO?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), ORKA (Oruka Therapeutics Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), NEOG (Neogen Corporation). Compare TKNO side-by-side with any of them on Quantisnow.How can I track TKNO on Quantisnow?
Quantisnow aggregates Alpha Teknova Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TKNO to receive live email and push alerts on every new disclosure.